Finally, we aim to explore the possible mechanism of SGLT2 inhibitors in improving HPO axis dysfunction and provide a theoretical basis for further research in reproductive endocrine and metabolic diseases. This evidence concerns the gene SLC5A2 and Other metabolic disease.